Unknown

Dataset Information

0

Alterations in platelets during SARS-CoV-2 infection.


ABSTRACT: Coronavirus disease 2019 (COVID-19) is a pandemic syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection induces a process of inflammation and thrombosis supported by an altered platelet activation state. This platelet activation is peculiar being characterized by the formation of platelet-leukocytes rather than platelet-platelet aggregates and by an increased procoagulant potential supported by elevated levels of TF positive platelets and microvesicles.Therapeutic strategies targeting, beyond systemic inflammation (i.e. with tocilizumab, an anti interleukin-6 receptor), this state of platelet activation might therefore be beneficial. Among the antithrombotic drugs proposed as candidates to treat patients with SARS-CoV-2 infection, antiplatelet drugs, such as aspirin are showing promising results.

SUBMITTER: Brambilla M 

PROVIDER: S-EPMC8425443 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-SCDT-EMBOR-2021-54341-T | biostudies-other
| S-SCDT-EMM-2021-14122 | biostudies-other
| S-SCDT-10_1038-S44318-024-00061-0 | biostudies-other
| 12454 | ecrin-mdr-crc
2013-07-31 | E-GEOD-47960 | biostudies-arrayexpress
2013-07-31 | E-GEOD-47961 | biostudies-arrayexpress
2013-07-31 | E-GEOD-47962 | biostudies-arrayexpress
| S-SCDT-EMBOJ-2020-106501 | biostudies-other
| S-EPMC10565689 | biostudies-literature
2023-09-28 | GSE234487 | GEO